BURLINGTON, Mass., Dec. 14, 2011 (GLOBE NEWSWIRE) -- Coronado Biosciences, Inc., (OTCBB:CNDO), a biopharmaceutical company focused on the development of novel immunotherapy agents for the treatment of autoimmune diseases and cancer, today announced the Australian Patent Office accepted the foundation patent application directed to CNDO-109, Coronado's activated natural killer (NK) cell program. The patent will issue shortly as a Deed of Letters Patent bearing Serial No. 2006224313, entitled, "Method for activating natural killer cells by tumor cell preparation in vivo."
